Skip to main content
. 2017 Oct 12;7(4):12. doi: 10.3390/jpm7040012

Figure 6.

Figure 6

Schematic representation of the Quality by Design approach, recommended by the FDA for the development of novel nanomedicines. Adapted from [83].